Company Name: Avita Medical
Announcement Date: 11/07/2016
Announcement Category: Investment
Announcement Content:
Avita Medical Rights Issue raises $9 million
Northridge, CA and Cambridge, United Kingdom, Perth, Australia, 11 July 2016 – Avita Medical Ltd (ASX: AVH), (OTCQX: AVMXY) today announced it has raised $9 million in a partially underwritten Rights Issue to support the Company’s strategy to launch in the US and push forward with product commercialization.
Avita, which manufactures portable cell-harvesting devices that can be used to treat burns, chronic wounds and skin defects, said the Rights Issue closed on July 4, and that net proceeds would be applied as described under the Offer Document lodged on the ASX on June 16, 2016.
“The Company wishes to thank our shareholders for their support at this exciting stage of Avita’s development,” said Avita CEO Adam Kelliher. “We have some crucial upcoming milestones, both clinically and commercially, and we will keep building value around our unique regenerative medicine approach.”
Read more here: http://bit.ly/29Ah3Gc
Announcement URL: http://www.asx.com.au/asxpdf/20160711/pdf/438h4k2nkj0hlt.pdf
About Avita Medical:
Avita Medical is a medical device company that transforms lives through its unique and innovative skin regeneration solutions. We are a publicly listed, global medical technology company trading on the Australian Stock Exchange (ASX:AVH) and OTC Markets (OTCQX:AVMXY). We develop and distribute highly innovative regenerative products including ReCell, the revolutionary 'spray-on skin' invented by West Australian Professor Fiona Wood.
Go to Company Profile for: Avita Medical
Announcement Contact: [email protected]
